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The nitric oxide (NO) and cyclooxygenase (COX) pathways
share a number of similarities. NO is the mediator generated
from the NO synthase (NOS) pathway and COX converts
arachidonic acid to prostaglandins (PGs), prostacyclin, and
thromboxane A2. Two major forms of NOS and COX have
been identified to date. The constitutive isoforms of these
enzymes play an important role in the regulation of several
physiological states. On the other hand, in an inflammatory
setting, the inducible isoforms of these enzymes are induced
in a variety of cells resulting in the production of large
amounts NO and PGs, which play pathological roles in several
disease states. An important link between the NOS and COX
pathways was made by our group when we demonstrated
that NO activates the COX enzymes, an event leading to overt
production of PGs, suggesting that COX enzymes represent
important endogenous ‘receptor’ targets for modulating the
multifaceted roles of NO. More importantly, mechanistic
studies of how NO activates the COX enzymes have been
undertaken and additional pathways through which NO
modulates PG production unraveled. The purpose of this
article is to cover the advances, which have occurred over the
years and in particular to summarize experimental data that
outline how the discovery that NO modulates PG production
has impacted and extended our understanding of these two
systems in physiopathological events.
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BIOSYNTHESIS OF NO AND PROSTAGLANDINS
Nitric oxide (NO) is generated via the oxidation of the
terminal guanidino nitrogen atom of L-arginine by nitric
oxide synthase (NOS). Three major isoforms of NOS have
been identified. These are distinct from each other based on
their primary amino-acid sequence (only 50–60% identity),
tissue and cellular distribution, and mode of regulation. Two
expressed, constitutively, are calcium/calmodulin-dependent
and are classified together as constitutive NOS isoforms
(cNOS): endothelial-derived NOS and neuronal-derived
NOS (nNOS). The third is a cytokine-inducible, calcium/
calmodulin-independent isoform of NOS (iNOS).1 The
distinct properties of each of the NOS isoforms have
important implications, as it is the magnitude, the duration
and the cellular sites of NO production, which determine its
overall physiological or pathophysiological effect. For exam-
ple, release of NO from cNOS occurs in small amounts and
for a short period of time. NO released under these
circumstances plays a crucial role in the cardiovascular
system where it controls organ blood flow distribution,
inhibits the aggregation and adhesion of platelets to the
vascular wall, inhibits leukocyte adhesion and smooth muscle
cell proliferation.1 In contrast, the iNOS isoform is expressed
in a wide variety of cells in response to inflammatory stimuli,
such as cytokines and lipopolysaccharide. The net result is a
delayed (typically 4–6 h) but prolonged synthesis of high
levels of NO. It is now well accepted that NO released from
iNOS is involved in several pathological events1–3 (Figure 1).
For example, the implication of NO, produced via iNOS,
in the pathophysiology of renal ischemia/reperfusion (I/R)
injury was investigated evaluating the effect of the iNOS
inhibitors, L-N6-(1-iminoethyl)lysine and aminoethyl-iso-
thiourea, on1 renal dysfunction and injury mediated by
bilateral I/R of rat kidneys in vivo as well2 cytokine-
stimulated NO production by primary cultures of rat
proximal tubule (PT) cells.4 L-N6-(1-iminoethyl)lysine
(3 mg/kg IV bolus 15 min before I/R followed by 1 mg/kg/h
throughout I/R) or aminoethyl-isothiourea (1 mg/kg IV
bolus 15 min before I/R followed by 1 mg/kg/h throughout
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I/R) significantly reduced the I/R-mediated increases of
serum creatinine (glomerular dysfunction), fractional excre-
tion of Naþ (tubular dysfunction), serum aspartate amino-
transferase (I/R injury) and urinary N-acetyl-b-D-
glucosaminidase (tubular injury).4 Moreover, the role of
iNOS was also investigated using iNOS/ mice were
subjected to bilateral renal ischemia (30 min) followed by
reperfusion (24 h). In particular in this experimental setting,
it has been demonstrated that GW274150 also reduced the
renal dysfunction in wild-type mice to levels similar to that
observed in iNOS/ mice subjected to I/R.5 All these
experimental evidences suggest that:1 an enhanced formation
of NO by iNOS contributes to the pathophysiology of renal I/
R injury and2 iNOS inhibitors reduces I/R injury of the
kidney.
The prostaglandins (PGs) are formed by the action of the
PG synthase in a two-step conversion of arachidonic acid.
First, the enzyme converts arachidonic acid to a cyclic
endoperoxide (PGG2) by the action of cyclooxigenase (COX),
which is then followed by a peroxidase that cleaves the
peroxide to yield the endoperoxide (PGH2).
6 These unstable
intermediate products of arachidonic acid metabolism by
COX are then rapidly converted to the PGs (e.g. PGE2, PGF2,
TXA2a, PGI2) by specific isomerase enzymes.
6 COX was first
purified from the sheep seminal vesicle, a prodigious source
of the protein7–10 as a homodimer of approximate molecular
mass of 140 kDa and subsequently cloned from the same
tissue.9,10 With the availability of the cDNA encoding the
protein and specific antibodies, numerous studies were
performed to evaluate the distribution, expression, and
regulation of COX both in vitro and in vivo.
Initially, it was thought that COX was a single enzyme that
produced PGs in most tissues and cell types. However, a
number of studies have illustrated that COX activity is
increased in certain inflammatory states and is induced in
cells by pro-inflammatory cytokines and growth factors in
vitro.11–13 Following these observations, extensive research in
this field led to the discovery that two forms of COX exist.
The constitutive isoform (COX-1) is present in tissues such
as the stomach, gut, or kidney, where PGs production plays a
cytoprotective role in maintaining normal physiological
processes.14 In inflammatory processes, the inducible isoform
of cyclooxygenase (COX-2) is expressed in many cells,
including fibroblasts and macrophages and accounts for the
release of large quantities of proinflammatory PG at the site
of inflammation14 (Figure 1). Selective inhibition of COX-2
is anti-inflammatory and inhibits nociception.15,16
The NOS and COX systems are often present together,
share a number of similarities and play fundamental roles in
similar physiopathological conditions.14 Increasing evidence
suggest that there is considerable ‘cross-talk’ between COX
and NOS.
REGULATION OF COX BY NOS
The discovery that NO regulates COX activity was originally
made using cellular systems and purified enzymes. Micro-
somal sheep vesicles are a rich source of COX-1 and can thus
be used to explore whether the exogenous application of NO
can augment further COX-1 activity.17 NO gas directly
increases COX-1 activity of microsomal sheep seminal
vesicles as well as murine recombinant COX-1; this leads to
a remarkable sevenfold increase in PGE2 formation.
18,19
COX-2 is also activated by NO. Indeed, evidence exists that
COX-2 but not iNOS is induced in human fetal fibroblast by
interleukin (IL)-1b. Therefore IL-1b stimulated fibroblasts
can be used as a cellular model to investigate the effects of
exogenous NO on COX-2 activity.18 Exposure of IL-1b
stimulated fibroblasts to either NO gas or two NO donors,
sodium nitroprusside and glyceryl trinitrate, increased COX-
2 activity by at least fourfold; this resulted in increased
production of PGs. More recently, NO was shown to enhance
the release of prostacyclin from endothelial cells and by this
mechanism NO and NO-stimulated prostacyclin contribute
to the marked anti-platelets effects associated with the
administration of nitrovasodilators.20 This observation is
also in keeping with earlier work illustrating synergies
between the vascular action of NO and prostacyclin.21 The
ability of NO to directly activate COX-2 was supported by the
evidence that NO increases the activity of purified recombi-
nant COX-2 enzymes. Having observed that NO activates
COX-1 and COX-2 enzymes, we addressed whether COX-2
activity was affected by endogenously produced NO. In this
respect, the mouse macrophage cell line RAW-264.7 was
stimulated with endotoxin so as to induce iNOS and COX-2
enzymes. This results in the production of large amounts of
NO and PGs. Inhibition of iNOS activity by non-selective
and selective NOS inhibitors21–24 attenuated, as expected, the
release of NO from these cells. The remarkable finding made
at the time was that when NO release was inhibited, there was
a simultaneous inhibition of PG release.18 The NOS
inhibitors do not inhibit COX activity.18,25,26 These results
suggested that endogenously released NO from macrophages
exerted a stimulatory action on COX-2 enhancing the
production of PGs. Activation of the enzyme has been
observed in various cellular systems27–32 and seems to be
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Figure 1 | Roles of iNOS and COX-2 in inflammation.
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independent of the known effects of NO on the soluble
guanylyl cyclase. Thus, methylene blue, an inhibitor of the
soluble guanylyl cyclase inhibited the increase in cyclic 30,50
guanosine monophosphate induced by NO in the fibroblast
but did not prevent its ability to stimulate COX activity and
hence PG production. Such observations were confirmed in
cells of the central nervous system, such as astrocytes. Here,
activation of the NMDA receptor by glutamate releases NO,
which in turn activate COX.29 These observations are
important in an attempt to understand pathophysiological
mechanisms driven by overt activation of the glutamatergic
neurotransmission such as for instance, stroke and pain. In
addition, spontaneous release of PGE2 by hypoxic astrocytes
occurs mainly via IL-1b-dependent activation of iNOS.33
Similar results where obtained in astroglial cells stimulated
with IL-1b and tumor necrosis factor-a.34 The observations
that NO regulates COX was extended in vivo in several
experimental models: hydronephrosis,35 sepsis,36 acute in-
flammation,37 and pain.38 Finally, some evidence generated
from in vitro studies exist to suggest that NO can inhibit PG
formation in vascular endothelial cells,39 rat Kuppfer cells40
and a macrophage cell line J774.41
PHYSIOLOGICAL IMPLICATION OF THE RECIPROCAL REGU-
LATION OF COX/NOS
The activation of COX-1 by NO released from the
constitutive form of NOS has important consequences in
normal physiological conditions. Production of small
amounts of NO and PGs from the constitutive enzymes
regulate various physiological processes, including the
inhibition of platelet aggregation and white blood cell
adhesion, regulation of blood vessel tone, cytoprotection in
the kidney, and intestinal mucosa. The main difference
between the effects of NO and PGs in mediating these effects
lies at the level of their respective intracellular transduction
mechanisms. Thus, NO activates the soluble guanylate cyclase
leading to increased cyclic 30,50 guanosine monophosphate
and PGs activate the adenylate cyclase leading to increase in
cAMP.
Another interesting effect of NO on COX-1 is perhaps in
the regulation of neuropeptide release. Norepinephrine
mediates the release of luteinizing hormone-releasing hor-
mone from its terminals and it is known that luteinizing
hormone-releasing hormone released from these terminals
requires increased release of PGE2.
42 In an elegant study,
Rettori et al.42 demonstrated that the release luteinizing
hormone-releasing hormone following norepinephrine-sti-
mulated hypothalamic slices was prevented by NOS inhibi-
tion and subsequent blockade of norepinephrine-mediated
PGE2 release. These results have opened the possibility that
through COX activation, NO may mediate exocytosis of
secretory granules not only for luteinizing hormone-releasing
hormone but also for other neuropeptides that are released
by PG E2. NO-driven COX-1 activation also seems to
have a role in reproduction in that NO also modulates
uterine motility43 by activating COX-1 and releasing PGE2.
Moreover, the recent observation about the dual inhibition of
NO and PG by non-selective NOS inhibitors may well
explain the deleterious effects observed with these drugs in
organs such as the kidneys and the gastrointestinal tract
where both NO and PG are cytoprotective. Recently, Wallace
and Fiorucci44 in a very interesting article published on
Trends in Pharmacological Science tried to comments these
two different aspects. There is large evidence to support the
claim that selective inhibitors of COX-2 produce less gastric
damage than standard nonsteroidal anti-inflammatory drug
(NSAID) when administered acutely to healthy animals.45
However, it has been also demonstrated that most patients
taking standard NSAID do not develop clinically significant
gastric injury; rather, it occurs in a subset of patients who are
more susceptible to the gastric-damaging actions of these
drugs.46 Moreover, the presence of both isoforms in the
vasculature raises the question of which is the predominant
cause of the increased production of vasodilator PGs that are
critical to the preservation of renal blood flow in the presence
of volume depletion. Inhibition of this homeostatic response
accounts for the most common renal side effects associated
with nonselective NSAID therapy.47
In particular, it has been demonstrated that combinations
of NSAIDs, taken in large doses over a prolonged period,
cause a specific form of kidney disease, characterized by
papillary necrosis and interstitial scarring.48 The patients
have progressive chronic renal failure and are susceptible to
the subsequent development of uroepithelial tumors. It is not
clear what the mechanism of the drug toxicity is, but there
are many theories, including the effects of COX inhibition,
direct toxicity owing to elevated concentration of the drugs in
the medulla, anoxia, and metabolic effects.49
The potential interaction of NO and COX-1 and its
implications in reproduction remains an exciting area for
future investigation.
The discovery that NO activates COX-1 enzyme has
uncovered additional mechanisms by which NO donors
might exert their beneficial effects in the clinic. It is known
that NO release from clinically useful NO donors such as
glyceryl trinitrate or 3-morpholinosydnonimine (SIN-1)
accounts for their vasodilatory and antithrombotic actions
and that these properties are pertinent to the therapeutic
effects of the NO donors in conditions, such as myocardial
ischemia, thrombosis, and atherosclerosis that are associated
with a failing endogenous NO pathway.50 For instance, as NO
donors do not require an intact endothelium in order to be
effective,51 they can restore the desired vascular dilation and
suppress platelet aggregation despite advanced atherosclero-
sis.52,53 The cardiovascular effects exerted by endogenously
produced NO are often mediated in conjunction with
prostacyclin, a potent vasodilator and platelet inhibitory
COX metabolite released from the endothelium. NO released
from the NO donors activates COX-1 in vitro in endothelial
cells as well as in vivo promoting the release of prostacy-
clin.54,55 The vasodilator and antithrombotic effects of NO
(and NO donors) is due to NO-stimulated soluble guanylate
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cyclase activation and cyclic 30,50 guanosine monophosphate
elevation and NO-mediated activation of COX in the
endothelial cells leading to prostacyclin formation and cAMP
elevation.55
This raises the possibility that the increased platelet
aggregation, vasoconstriction and elevation of systemic blood
pressure induced by inhibition of endogenous NO produc-
tion by non-selective NOS inhibitors could be due not only
to removal of endogenous NO but also to a concurrent
reduction of antiplatelet and vasodilator COX products.
In this regard, recently, it has been demonstrated that the
COX-inhibiting NO donors (CINODs), a new class of agents
designed for the treatment of pain and inflammation, have a
multi-pathway mechanism of action that involves COX
inhibition and NO donation. In particular is important to
point out that these agents are devoid of hypertensive effects
in animal models and their mechanism of action suggests
that they may not cause edema, they prevent platelet
activation in vitro, exhibit anti-thrombotic activity in vivo
as well as other renal-sparing effects, being better tolerated
than NSAIDs in models of kidney failure.56
PATHOPHYSIOLOGICAL IMPLICATION OF THE RECIPROCAL
REGULATION OF COX/NOS
In vivo studies revealed that the regulation of COX by NO is a
powerful mechanism that is used by NO to amplify the
course of the inflammatory response. Thus, iNOS and COX-
2 are induced in a number of inflammatory models,
including rabbit hydronephrotic kidney,35 endotoxin-in-
duced septic shock19,57 and carrageenan-induced pouch,
and paw inflammation.58–60 In these settings, inhibition of
NO inhibits both NO and PG release; the anti-inflammatory
potency of the iNOS inhibitors correlated with their
respective ability to block both NO and PGs.18,19,25,58,61–66
For instance, in an acute model of inflammation, namely
carrageenan-induced paw edema in rats, inhibition of edema
with L-N6-(1-iminoethyl)lysine is associated with a dose-
dependent inhibition of NO and a clear inhibition of
proinflammatory PGs.59 That the proinflammatory roles of
NO have a PG component has also been demonstrated by
showing that the injection of sodium nitroprusside elicits
edema in the footpad of rats and this formation of edema is
blocked by NSAIDs.65 Therefore, the effects of endogenously
released NO on COX-2 are mimicked by exogenous NO.
Inhibition of NOS in lungs taken from endotoxin-treated rats
resulted in an inhibition of PGI2 release.
66 In acute
pancreatis, the increased production of PGs was inhibited
by NOS inhibitors indicating the participation of NO in this
process.67 Furthermore, injection of carrageenan into the
preformed air pouch of a rat induces an inflammatory
response characterized by iNOS and COX-2 induction, white
blood cell infiltration, edema, and protein leakage into the
pouch.57 Selective inhibition of iNOS by L-N6-(1-imi-
noethyl)lysine and aminoguanidine inhibited not only NO
but also PGs production. All other parameters of inflamma-
tion were attenuated and histological examination of the
pouch lining taken from animals treated with the iNOS
inhibitor revealed a lack of inflammation.57 Injection of NO
donors such as sodium nitroprusside or nitroglycerin into the
air pouch, activated COX-2 resulting in profound increase in
PGE2 release.
57 Similar results have been observed in other
studies.68
Recently, it has been demonstrated that NO reverses
endotoxin-induced inflammatory hyperalgesia via inhibition
of prostacyclin production, and also contributes to the
analgesic effect of nuclear factor (NF)-kB, COX, or PARS
inhibitors.69 Moreover, recently, it has been demonstrated
that treatment of diabetic rats with L-arginine analog N-nitro
L-arginine methyl ester prevents the upregulation of renal
COX-2 and the associated increase in renal PG release in
response to arachidonic acid, suggesting that NO or a
product of NO may contribute to the induction of COX-2 in
the diabetic rat.70 The induction of COX-2 in diabetes
appears to contribute to the renal functional and structural
changes associated with this condition as inhibition of COX-
2 has been shown to reduce glomerular filtration rate in the
diabetic rat71 and to reduce markers of renal injury in
hypertensive diabetic rats.72 In this content, it is well
documented that COX-2 and nNOS are coexpressed in
macula densa cells and that the expression of both enzymes is
stimulated in a number of high-renin states. In particular, it
has been demonstrated that the plasma renin activity was
significantly reduced in nNOS / mice on a mixed genetic
background and in COX-2 / mice on either BALB/c or
C57/BL6 congenic backgrounds.73 In additional studies,
various evidence have point out an inhibitory influence of
PGE2 on nNOS expression. In particular, in cultured macula
densa cell line, PGE2 significantly reduced nNOS mRNA
expression. In COX-2 / mice, nNOS mRNA expression in
the kidney was upregulated throughout the postnatal periods.
The induction of nNOS protein expression and NOS activity
in COX-2 / mice was localized to macula densa cells.
Therefore, these findings reveal that the absence of either
COX-2 or nNOS is associated with suppressed renin
secretion.73 Furthermore, the inhibitory effect of PGE2 on
nNOS mRNA expression indicates a novel interaction
between NO and PG-mediated pathways of renin regula-
tion.73
MOLECULAR MECHANISMS INVOLVED IN THE RECIPROCAL
REGULATION OF NOS/COX
We had initially proposed that NO increased PG formation
by acting the COX enzyme. At that time, we did not have a
mechanistic explanation to support how this occurred. As
reported by Tsai et al.,74 it is unlikely that NO activates COX
by binding directly to its heme prostetic group. Over the
years, various possibilities have been set forth and these are
depicted in Figure 2. The first possibility is that NO acts as an
antioxidant. Indeed, COX activity also provides a source of
superoxide anion, and it has been postulated that superoxide
could be involved in the auto-inactivation of COX enzymes.75
NO interacts with superoxide and limits the amounts of the
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radical necessary for auto-inactivation.76 One possibility
could therefore be that NO augments COX activity by
removing superoxide and acting as an antioxidant preventing
the auto-inactivation of COX. The second possibility is the
formation of nitrosothiols. NO nitrosylates cysteine residues
in the catalytic domain of COX enzymes leading to the
formation of nitrosothiols; these can produce changes in the
structure of the enzyme, which results in increased catalytic
efficiency.77 The third possibility is the generation of
peroxynitrite, the coupling product of superoxide and NO.
Using purified COX-1 and COX-2 enzymes as well as sheep
seminal vesicles, Landino et al.78 reported that peroxynitrite
increased COX-1 and COX-2 activity. Peroxynitrite stimu-
lated COX-1 activity in aortic smooth muscle cells.79 The
mechanisms of action by which peroxynitrite can activate the
enzymes remain to be defined but could involve either
oxidative inactivation80 or modification of key amino acids
residues in the polypetide backbone.81 The forth possibility is
that iNOS binds to COX-2 and S-nitrosylates at C526,
enhancing its catalytic activity.82 This does not explain how
exogenous administration of NO or NO donors increases PG
generation in vitro. A similar role for the constitutive
enzymes remains to be established.
In addition to effects on COX-2 enzyme activity, NO has
been shown to increase the production of PGs from
macrophages by acting at post-transcriptional or transla-
tional level to increase COX-2 protein.32 In particular,
subsequent studies using human osteoarticular chondrocytes
revealed that NO released from sodium nitroprusside was
able to induce cell death, an event associated with DNA
fragmentation, caspase-3 activation, downregulation of Bcl-2,
overexpression of COX-2, and increased release of PGE2.
83
These events were abolished by blocking the mitogen-
activated protein kinase pathway with the mitogen-activated
protein kinase inhibitor PD98059, the p38 kinase with
inhibitor SB202190, and the COX-2 with selective inhibitor
NS-398. Interestingly, although PGE2 alone had no effect
on cell death, it did sensitize sodium nitroprusside-
mediated death. These results suggest that NO activates the
extracellular signal-related protein kinase and p38 kinase
pathway, which in turn induce COX-2 and subsequent PGE2
release. The latter, in turn, may sensitize human osteoarti-
cular chondrocytes to the cell death induced by NO.83
Similarly, the interaction between NO and COX-2 and the
signaling pathway involved was also investigated in primary
cultured rabbit cortical thick ascending limb.84 In these cells,
immunoreactive COX-2 and vasodilatory PGs were increased
by a NO donor, S-nitros-N-acetylpenicillamine by increasing
the expression of phosphorylated p38. In addition, the
administration of a low-salt diet increased immunoreactive
COX-2 and nNOS in the macula densa and surrounding
cortical thick ascending limb of kidneys of wild-type mice,
but did not significantly elevate COX-2 expression in
nNOS/ mice. All these results demonstrate that in cortical
thick ascending limb, NO can increase COX-2 expression in
cortical thick ascending limb and macula densa through p38-
dependent signaling pathways via activation of NF-kB.84
NO is also necessary for maintaining prolonged COX-2
gene expression26 and sustained PGE2 biosythesis. NO-
induced alterations in COX-2 gene expression were not
related to COX-2 mRNA26,85,86 and the mechanism through
which NO influences COX gene expression is not yet known.
In the last few years, increasing evidence suggest that
intracellular concentrations of NO and PGs may be relevant
in switching on/off inflammatory cells by modulating their
own biosynthesis and NOS/COX enzymes. Indeed, in human
fetal microglial cells, very low concentrations of constitutive
NO released by cNOS seem to be required in order to activate
COX expression.71 Furthermore, low amounts of NO
enhance prostanoid formation, whereas higher concentra-
tions downregulate COX pathway.41 Thus, the concentration
of endogenous or exogenous NO plays a crucial role in the
regulation of COX activity, though the mechanism of this
effect is still unclear.
Evidence exists that in cells possessing both cNOS and
iNOS, such as astroglial cells, as well as in cells expressing
only inducible iNOS, NO and NO donors are able to
regulate, according to the cell type and to the amount of NO
released, the expression of both constitutive and inducible
COX enzymes.87,88 In particular, evidence has been provided
that NO released under basal conditions by cNOS keeps
iNOS under a non-activated state through the inhibition of
the NF-kB signalling, which in turn regulates the iNOS
trascriptional mechanisms. NF-kB represents one of the most
relevant signalling pathway, which mediates the expression of
iNOS following many extracellular mediators, including
endotoxin and inflammatory cytokines.89–92 When low
concentration of endogenous as well as exogenous NO is
released, NF-kB is kept into an inactive state.92 Many factors
may contribute in NO-related inhibition of NF-kB, including
the direct effect of NO at the level of the binding of NF-kB to
its promoter response element, without affecting the activa-
tion and translocation of NF-kB.93,94 Moreover, NO has been
shown to inhibit NF-kB DNA binding through S-nitrosyla-
tion of the cys 62 residue of p50 subunit.95 However, further
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Figure 2 | Regulation of PG formation by NO.
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data have recently shown that NO interacts with NF-kB via
stabilization of its endogenous inhibitor IkB. In particular,
evidence has been collected indicating that NO and NO
donors stabilize interferon-kB by preventing its degradation
from NF-kB and increase the mRNA expression of
interferon-kB-a without affecting the mRNA expression of
NF-kB subunits p65 or p50.96 Thus, in cells in which iNOS is
activated by extracellular inducers of NF-kB, NO may exert
an early inhibitory role. When increasing concentrations of
NO are released, NF-kB is not suppressed by NO and may
contribute in iNOS activation, possibly via combination with
superoxide anions and peroxynitrite formation. As NF-kB is
also a potent inducer of COX-2 and the action of NO on
COX-2 is mediated by inhibition of NF-kB in mesangial
cells,97 it is likely that these mechanisms may underlie some
of the inhibitory effects of NO in PG biosynthesis.
CONCLUDING REMARKS
Compelling data have been generated over the last decade
supporting the concept that NO and/or other reactive species
such as peroxynitrite play an important role in regulating the
formation of PGs by COX enzymes. Thus, continuing to
understand the molecular, enzymatic and biochemical
mechanisms involved in such regulation will undoubtedly
elucidate important molecular targets for future pharmaco-
logical intervention.
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